Reference priceEUR €577.50Original source price: INR 52,500.00. Converted estimates are available by currency selection.
| Brand | Zynyz |
|---|---|
| Manufacturer | Incyte Corporation |
| Prescription required | Yes |
Zynyz 25mg/ml injection,1vial x 20ml(Retifanlimab-dlwr)
retifanlimab-dlwr
Description
Zynyz 25mg/ml injection,1vial x 20ml(Retifanlimab-dlwr) is a medicine catalog record in the MediPriceHub database. Active ingredient: retifanlimab-dlwr. Clinical use summary: See the Benefits field on this page for the product-specific indication or intended use. That field is kept separate from catalog metadata so users can distinguish clinical information from packaging information. Manufacturer or supplier: Incyte Corporation. Therapeutic category: Medicine Library > Oncology Medicines > Oncology Other Drugs. Pack information: 500 / 20 (25 / ). Origin country or market: United States. This page is for medicine catalog reference only and should be read together with the approved prescribing information in the patient or buyer's country.Benefits
ZYNYZ is a programmed death receptor-1 (PD-1)–blocking antibody indicated: Squamous Cell Carcinoma of the Anal Canal (SCAC) Merkel Cell Carcinoma (MCC) in combination with carboplatin and paclitaxel for the first-line treatment of adult patients with inoperable locally recurrent or metastatic squamous cell carcinoma of the anal canal (SCAC). as a single agent for the treatment of adult patients with locally recurrent or metastatic SCAC with disease progression on or intolerance to platinum-based chemotherapy. for the treatment of adult patients with metastatic or recurrent locally advanced Merkel cell carcinoma (MCC).How to Use
Use retifanlimab-dlwr under the supervision of a qualified healthcare professional. It should be prepared and administered only by trained healthcare professionals in a setting appropriate for injectable or infusion medicines. Do not start, stop, change the dose, split or crush a dosage form, mix with other medicines, or repeat a course unless the approved product information or a clinician confirms that it is appropriate. Check the local prescribing information for age limits, dose adjustments, missed-dose instructions, storage after opening or reconstitution, and monitoring requirements.Specification
Active ingredient: retifanlimab-dlwr. Pack size: 500 / 20 (25 / ). Pack unit: bottle. Manufacturer: Incyte Corporation. Origin country: United States. Source category: Medicine Library > Oncology Medicines > Oncology Other Drugs. Availability, prescription status, storage, and exact approved use may vary by country. Check the local product information before clinical or procurement decisions.Side Effects
The available source record does not provide a clean, product-specific adverse-reaction list. Potential risks depend on the active ingredient, dose, route, treatment duration, and patient condition. Check the approved local prescribing information for the complete adverse-reaction profile, warnings, contraindications, and monitoring requirements. Seek urgent medical care for severe allergic symptoms, breathing difficulty, fainting, severe skin reactions, chest pain, serious bleeding, or rapidly worsening symptoms.Esta información es solo orientativa. Consulta a un profesional sanitario antes de usar cualquier medicamento.